DVA · 10-Q · 2026Q2 · Full report

Regulatory Risk

DAVITA INC. · 2026-08-04 · Importance 44 · Surprise 60 · In source text

DaVita continues to face government investigations in the United States involving physician joint ventures, medical-director agreements, insurance communications, American Kidney Fund donations, and physician restrictive covenants. The U.S. Attorney’s Offices for New Jersey and the Eastern District of Pennsylvania are connected to False Claims Act proceedings, while the California Department of Insurance, District of Columbia Attorney General, and Federal Trade Commission are conducting separate inquiries; the FTC’s April 2024 CIDs cover January 1, 2016 through the present. Recorded legal and regulatory accruals were immaterial as of June 30, 2026, but adverse findings could result in substantial penalties, business-practice changes, contract impacts, or exclusion from Medicare and Medicaid programs.

Key facts

• CMS estimates proposed 2027 ESRD PPS rule will increase freestanding facilities’ average reimbursement by 1.1% in 2027 source
• The Company received two CIDs from the FTC in April 2024 covering period from January 1, 2016 to present related to industry investigation under Section 5 about acquisition of medical director services and provision of dialysis services source
• Cybersecurity incident-related patient care charges and G&A expenses incurred during the three and six months ended June 30, 2025: approximately $1.0 million patient care and approximately $12.5 million general and administrative source
• The 2020 U.S. Attorney New Jersey matter had a court dismissal without prejudice on April 13, 2022 and the Company's Corporate Integrity Agreement term expired October 22, 2019 (as referenced) source

Impact estimates